Emmes Appoints Matt Bond as CFO

Reportedly, Bond's expertise in mergers and acquisitions (M&A) and his track record with successful private-equity-backed enterprises are expected to be valuable assets in Emmes' growth and diversification strategy.

US-based Clinical Research Organisation (CRO), Emmes has named Matt Bond as its Chief Financial Officer (CFO) succeeding former CFO Brian Hochheimer.

This decision aligns with Emmes' objective of supporting the advancement of public health and biopharmaceutical innovation. By appointing a seasoned financial executive with a profound industry understanding, Emmes is positioning itself for sustained growth  and increasing its impact in the healthcare sector

Reportedly, Bond's expertise in mergers and acquisitions (M&A) and his track record with successful private-equity-backed enterprises are expected to be valuable assets in Emmes' growth and diversification strategy.

On his appointment, Bond said, 'œThis is a perfect time to join the company, as we continue to build our reputation with government and biopharma clients and ramp up our presence in new global markets. I'm able to hit the ground running because I've worked in this sector for decades and have been successful in generating profitable growth while partnering with great management teams.'

Before joining Emmes, Bond served as the CFO of Bracket (now Signant Health), a leading technology provider to the drug development market.  During his tenure, he oversaw the organisation's sustained growth including a successful sale of the company to another global, private-equity-backed firm.  

Prior to that, he cofounded Aptiv Solutions, a technology-focused CRO, where he played the key role of growing the company from a startup into a multinational organisation through the acquisition of over 10 companies.

Sharing his views, Peter Ronco, CEO, Emmes, said, 'œMatt combines a rich set of CFO experiences with a deep understanding of the biopharma and clinical technology solutions space. A seasoned executive with over 30 years of financial leadership experience, he has led the finance function for many successful, private-equity-backed companies in the pharmaceutical services and contract research market segment.'

Just a few days back, Emmes appointed Peter Ronco as CEO succeeding Dr Christine Dingivan, who has transitioned to the role of senior advisor to executive chairman Sastry Chilukuri and Emmes' Board of Directors. 

Ronco is an experienced global pharmaceutical executive with over two decades of leadership in various R&D positions. His most recent role was senior vice president of Global Development at Johnson & Johnson, where he oversaw the management and execution of a drug development portfolio comprising over 500 active clinical studies across all therapeutic areas and developmental phases. Ronco has also held senior positions at Bristol Myers-Squibb, Accenture, and Pfizer.

Founded in 1977, Emmes is a global, full-service Clinical Research Organisation (CRO) based in the United States. The organisation supports the advancement of public health and biopharmaceutical innovation. To date, it has conducted over 2000 clinical studies across a broad range of therapeutic areas, with significant expertise in infectious diseases, vaccines, ophthalmology, oncology, neurology, substance use disorders, and maternal and child health.

Currently, Emmes has offices throughout the US, Europe, Canada, and India. The company's annual revenue was approximately $110 million for FY 2022.

In a similar development, in September this year, Mankind Pharma appointed former VFS executive Tarun Kapoor as vice president. With this move, Mankind Pharma aims to make the company future-ready and upskill its digital strategy.